Skip to Content

'
Qiang Shen, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Qiang Shen, MD, PhD, is an Assistant Professor in the Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences at the University of Texas M. D. Anderson Cancer Center. He earned his PhD in Cell Biology from The University of Texas Medical Branch at Galveston in 2001. Dr. Shen then did a postdoc with Dr. Powel Brown at Baylor College of Medicine, Lester and Sue Smith Breast Center till 2006 and was then promoted to Instructor in the Departments of Medicine and Cellular & Molecular Biology. Dr. Shen joined the Department of Clinical Cancer Prevention at M.D. Anderson Cancer Center in 2009. Dr. Shen’s current research focuses on elucidating the mechanisms by which normal pancreatic and mammary cells are malignantly transformed into cancer cells. He is interested in identifying novel targets for the prevention and treatment of pancreatic and breast cancer. More specifically, Dr. Shen studies the activation of transcription factors, kinases, and ion channels in normal and cancer cells; using molecular, cellular and transgenic approaches. In addition, Dr. Shen recently obtained an NIH/NCI K22 Award to conduct a study on the AP-1 transcription factor in breast cancer metastasis.                                                                            .

Office Address

The University of Texas MD Anderson Cancer Center
Basic Science Research Building
1515 Holcombe Blvd.
Unit Number: 1013
Houston, TX 77030
Room Number: S7.8136B
Phone: 713-834-6357
Fax: 713-834-6350
Email: qshen@mdanderson.org

Education & Training

Degree-Granting Education

2002 The University of Texas Medical Branch, Galveston, TX, PHD, Cell Biology
1989 Kunming Medical College, Kunming, Yunnan, China, MD, MS, Medicine, General Surgery
1981 Jiangxi Medical College, Shangrao, Jiangxi, China, Diploma of Medicine, Medicine

Postgraduate Training

5/2002-12/2006 Postdoctoral, Cancer Biology, Baylor College of Medicine, Houston, TX, Mentor: Powel H. Brown, M.D., Ph.D.

Experience/Service

Academic Appointments

Postdoctoral Fellow, Baylor College of Medicine, Houston, TX, 5/2002-12/2006
Graduate Student and Research Assistant, The University of Texas Medical Branch, Galveston, TX, 9/1995-5/2002
House Surgeon and Attending Physician, Department of Surgery, Shekou Union Hospital, Shenzhen, Guangdong, China, 8/1989-8/1995
Fellow, Kunming Medical University, Kunming, Yunnan, China, 9/1986-7/1989
Physician (Surgeon), Guangfeng County Hospital, Shangrao, Jiangxi, China, 5/1984-8/1986

Other Appointments/Responsibilities

Committee Chair, Clinical Cancer Prevention Faculty Journal Club, Houston, TX, 9/2010-9/2012

Institutional Committee Activities

Member, Institutional Animal Care and Use Committee, 4/2010-5/2013

Honors and Awards

2007 AACR-Aflac Scholar-in-Training Award, American Association for Cancer Research

Selected Publications

Peer-Reviewed Original Research Articles

1. Chen H, Yang Z, Ding C, Xiong A, Wild C, Wang L, Ye N, Cai G, Flores RM, Ding Y, Shen Q, Zhou J. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). Eur J Med Chem 82C. e-Pub 5/2014. PMID: 24904966.
2. Ye N, Ding Y, Wild C, Shen Q, Zhou J. Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1). J Med Chem. e-Pub 5/2014. PMID: 24831826.
3. Zhou Q, Facciponte J, Jin M, Shen Q Lin Q. Humanized NOD-SCID IL2rg-/- Mice as a Preclinical Model for Cancer Research and Its Potential Use for Individualized Cancer Therapies. Cancer Lett 344(1):13-9, 3/2014. e-Pub 10/2013. PMID: 24513265.
4. Tu H, Sun H, Lin Y, Ding J, Nan K, Li Z, Shen Q, Wei Y. Oxidative Stress Upregulates PDCD4 Expression in Patients with Gastric Cancer via miR-21. Curr Pharm Des 20(11):1917-23, 2014. e-Pub 7/2013. PMID: 23888942.
5. Xiong A, Yang Z, Shen Y, Zhou J, Shen Q. Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel) 6(2):926-57, 2014. e-Pub 4/2014. PMID: 24743778.
6. Ding C, Zhang Y, Chen H, Yang Z, Wild C, Ye N, Ester CD, Xiong A, White MA, Shen Q, Zhou J. Oridonin Ring A-Based Diverse Constructions of Enone Functionality: Identification of Novel Dienone Analogues Effective for Highly Aggressive Breast Cancer by Inducing Apoptosis. J Med Chem. e-Pub 10/2013. PMID: 24128046.
7. Yang Z, Chen H,Ding C, Wild C, Zhou J and Shen Q. Targeting STAT3 Signaling for the Prevention of ER-negative Breast Cancer. 12th AACR International Conference on Frontier of Cancer Prevention Research, 10/2013.
8. Zhou F, Shen Q, Claret FX. Novel Roles of Reactive Oxygen Species in the Pathogenesis of Acute Myeloid Leukemia. J Leukoc Biol 94(3):423-9, 9/2013. e-Pub 5/2013. PMID: 23715741.
9. Meng X, Cai C, Wu J, Cai S, Ye C, Chen H, Yang Z, Zeng H, Shen Q, Zou F. TRPM7 Mediates Breast Cancer Cell Migration and Invasion Through the MAPK Pathway. Cancer Lett 333(1):96-102, http://dx.doi.org/10.1016/j.canlet.2013.01.031, 6/2013. e-Pub 1/2013. PMID: 23353055.
10. Chen H, Yang Z, Ding C, Chu L, Zhang Y, Terry K, Liu H, Shen Q*, Zhou J*. Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents. ACS Med Chem Lett 4(2):180-185, 2/2013. e-Pub 2/2013. PMCID: PMC3583367.
11. Chen H, Yang Z, Ding C, Chu L, Zhang Y, Terry K, Liu H, Shen Q*, Zhou J*. Fragment-Based Drug Design and Identification of HJC0123, A Novel Orally Bioavailable STAT3 Inhibitor for Cancer Therapy. Eur J Med Chem 62. e-Pub 1/2013. PMID: 23416191.
12. Ding C, Zhang Y, Chen H, Wild C, Wang T, White MA, Shen Q, Zhou J. Overcoming Synthetic Challenges of Oridonin A-Ring Structural Diversification: Regio- and Stereoselective Installation of Azides and 1,2,3-Triazoles at the C-1, C-2, or C-3 Position. Org Lett 15:3718-3721, 2013. PMID: 23834026.
13. Li Y, Shen Q, Kim HT, Bissonnette RP, Lamph WW, Yan B, Brown PH. The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor. Breast Cancer Res Treat 128(3):667-77, 8/2011. e-Pub 9/2010. PMID: 20821348.
14. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst 101(2):107-13, 1/2009. e-Pub 1/2009. PMCID: PMC2639315.
15. Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, Brown PH. Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 284(1):345-53, 1/2009. e-Pub 10/2008. PMCID: PMC2610495.
16. Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH. Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila Pa) 1(1):45-55, 6/2008. e-Pub 3/2008. PMCID: PMC2577387.
17. Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer 98(8):1380-8, 4/2008. e-Pub 3/2008. PMCID: PMC2361704.
18. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 27(3):366-77, 1/2008. e-Pub 7/2007. PMID: 17637753.
19. Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW, Brown PH. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res 13(20):6224-31, 10/2007. PMID: 17947490.
20. Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH. The AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol 295(2):589-603, 7/2006. e-Pub 4/2006. PMID: 16678816.
21. Lu C, Shen Q, DuPré E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. Oncogene 24(43):6516-24, 9/2005. PMID: 16027729.
22. Shen Q, Brown PH. Transgenic mouse models for the prevention of breast cancer. Mutat Res 576(1-2):93-110, 8/2005. PMID: 15888345.
23. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene 23(50):8238-46, 10/2004. PMID: 15378019.
24. Shen Q, Singh P. Identification of a novel SP3 binding site in the promoter of human IGFBP4 gene: role of SP3 and AP-1 in regulating promoter activity in CaCo2 cells. Oncogene 23(14):2454-64, 4/2004. PMID: 14767471.
25. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95(24):1825-33, 12/2003. PMID: 14679152.
26. Shen Q, Brown PH. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 8(1):45-73, 1/2003. PMID: 14587863.
27. Fan X, Croll RP, Wu B, Fang L, Shen Q, Painter SD, Nagle GT. Molecular cloning of a cDNA encoding the neuropeptides APGWamide and cerebral peptide 1: localization of APGWamide-like immunoreactivity in the central nervous system and male reproductive organs of Aplysia. J Comp Neurol 387(1):53-62, 10/1997. e-Pub 1997. PMID: 9331171.

Abstracts

1. Yusong Zhang, Chunyong Ding, Zhengduo Yang, Haijun Chen, Lili Chu, Jia Zhou, Shen Q. Discovery of Potent Oridonin Derivatives for the Treatment of Breast Cancer. 2013 AACR Annual Meeting, 2013.
2. Zhengduo Yang, Haijun Chen, Lili Chu, Yusong Zhang, Chunyong Ding, Huiling Liu, Jia Zhou, Shen Q. Novel Potent and Orally Active STAT3 Inhibitors for Cancer Therapies. 2013 AACR Annual Meeting, 2013.
3. Shen Q, Brown PH. The TASK2 potassium ion channel is differentially expressed in ER-negative breast cancer. 8th Annual AACR International Conference on Frontiers in Cancer Prevention Research, 2009.

Grant & Contract Support

Title: HIPK4 Kinase Emerges As A Novel Driver Gene To Promote Cancer Metastasis
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 7/1/2014 - 6/30/2018
 
Title: Targeting STAT3 for the Prevention of ER-negative Breast Cancer
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 7/1/2014 - 6/30/2018
 
Title: Preventing ER-negative and Triple-negative Breast Cancer by Targeting STAT3 Signaling
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 7/1/2014 - 6/30/2017
 
Title: Novel Bax Activators as Targeted Therapy for Triple-Negative Breast Cancer
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 7/1/2014 - 6/30/2017
 
Title: Novel Role of Homeodomain Interacting Protein Kinase 4 (HIPK4) in Promoting Breast Cancer Metastasis
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 7/1/2014 - 6/30/2017
 
Title: Chemoprevention of ER-negative Breast Cancer by Targeting STAT3 Transcription Factor
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/1/2014 - 8/31/2019
 
Title: Study of A Novel Metastasis Driver Gene HIPK4 for the Treatment and Prevention of Cancer Metastasis
Funding Source: Paredee Foundation
Role: Principal Investigator
Duration: 1/15/2014 - 1/14/2016
 
Title: Targeting STAT3 Signaling Pathway to Prevent ER-negative Breast Cancer
Funding Source: PreventCare
Role: Principal Investigator
Duration: 1/15/2014 - 1/14/2016
 
Title: Targeting STAT3 for the Prevention of ER-negative Breast Cancer
Funding Source: DFI
Role: Principal Investigator
Duration: 12/1/2012 - 11/30/2014
 
Title: Photonic Crystal Microarray Nanoplatform as a personalized diagnostic assay for high thoughput detection and identification of cancers
Funding Source: NIH/NCI
Role: Collaborator
Duration: 9/28/2012 - 9/27/2014
 
Title: A new role of potassium ion channel KCNCK5 in breast carcinogenesis
Funding Source: MDACC
Role: Principal Investigator
Duration: 4/1/2011 - 3/31/2012
 
Title: Fund to initiate independent cancer research programs for prevention, early detection and diagnosis, and treatment of various cancers.
Funding Source: MDACC
Role: Principal Investigator
Duration: 11/1/2009 - 10/31/2014
 
Title: Targeting the AP-1 transcription factor for the prevention of metastasis from breast cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/18/2009 - 8/31/2012
 
Title: Targeting the AP-1/ER crosstalk for the prevention and treatment of breast cancer
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Brown
Duration: 9/1/2009 - 1/31/2012
 
Title: SPORE in Breast Cancer Career Development
Funding Source: NIH/NCI
Role: Awardee
Principal Investigator: Osborne
Duration: 1/1/2006 - 11/30/2009

Last updated: 4/25/2014